Theravance Biopharma (TBPH) Operating Leases (2019 - 2026)

Theravance Biopharma (TBPH) has 8 years of Operating Leases data on file, last reported at $29.8 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $29.8 million, down 20.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $29.8 million (down 20.34% YoY), and the FY2025 annual result was $31.8 million, down 18.79% from the prior year.
• Operating Leases retreated to $29.8 million in Q1 2026 per TBPH's latest filing, from $31.8 million in the prior quarter.
• Over five years, Operating Leases peaked at $51.4 million in Q3 2022 and troughed at $29.8 million in Q1 2026.
• A 5-year average of $41.3 million and a median of $42.4 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2024 and 2026: Operating Leases gained 0.18% in 2024, then declined 20.34% in 2026.
• A 5-year view of Operating Leases shows it stood at $45.4 million in 2022, then decreased by 0.38% to $45.2 million in 2023, then dropped by 13.55% to $39.1 million in 2024, then slipped by 18.79% to $31.8 million in 2025, then declined by 6.32% to $29.8 million in 2026.
• Business Quant data shows TBPH's Operating Leases at $29.8 million in Q1 2026, $31.8 million in Q4 2025, and $33.7 million in Q3 2025.